Blockade of TIPE2-Mediated Ferroptosis of Myeloid-Derived Suppressor Cells Achieves the Full Potential of Combinatory Ferroptosis and Anti-PD-L1 Cancer Immunotherapy
Although immune checkpoint blockade (ICB) therapy has attained unprecedented clinical success, the tolerance and immune suppression mechanisms evolved by tumor cells and their tumor microenvironment (TME) hinder its maximum anti-cancer potential. Ferroptosis therapy can partially improve the efficac...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/14/2/108 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832588836001021952 |
|---|---|
| author | Hafiza Kashaf Tariq Zihao Liang Lawan Rabiu Abdulrahman Ibrahim Nada Mohamady Farouk Abdalsalam Rong Li Qiong Yang Xiaochun Wan Dehong Yan |
| author_facet | Hafiza Kashaf Tariq Zihao Liang Lawan Rabiu Abdulrahman Ibrahim Nada Mohamady Farouk Abdalsalam Rong Li Qiong Yang Xiaochun Wan Dehong Yan |
| author_sort | Hafiza Kashaf Tariq |
| collection | DOAJ |
| description | Although immune checkpoint blockade (ICB) therapy has attained unprecedented clinical success, the tolerance and immune suppression mechanisms evolved by tumor cells and their tumor microenvironment (TME) hinder its maximum anti-cancer potential. Ferroptosis therapy can partially improve the efficacy of ICB, but it is still subject to immune suppression by myeloid-derived suppressor cells (MDSCs) in the TME. Recent research suggests that an MDSC blockade can unleash the full therapeutic potential of the combined therapy of ferroptosis and ICB in liver cancer treatment. However, whether blocking the intrinsic ferroptosis pathways of MDSCs can relieve imidazole ketone erastin (IKE)-initiated ferroptosis-induced immune suppression and ultimately trigger the optimal therapeutic effect of the combined ferroptosis and ICB therapy is still unknown. Here, we report that TIPE2, a phospholipid transfer protein, regulated the ferroptosis susceptibility in MDSCs through reprogramming lipid peroxidation-related phosphatidylethanolamine (PE) and phosphatidylcholine (PC) species composition. TIPE2-deficient MDSCs resisted IKE-induced ferroptosis by up-regulating SLC7A11 and GPX4, and dissolved ferroptosis-induced immunosuppressive function by down-regulating lipid ROS whilst encouraging T cell proliferation and infiltration into tumor tissues to improve ferroptosis therapy. More importantly, TIPE2-deficient MDSCs achieved the full anti-tumor therapeutic potential of IKE-induced ferroptosis therapy and a PD-L1 blockade. These findings indicate that TIPE2 confers the ferroptosis sensitivity of MDSCs, and combining the targeting of the TIPE2 of MDSCs, ferroptosis therapy, and ICB is a novel therapeutic option for cancer treatment. |
| format | Article |
| id | doaj-art-5536f256ce99442390e78f7f4545256a |
| institution | Kabale University |
| issn | 2073-4409 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj-art-5536f256ce99442390e78f7f4545256a2025-01-24T13:26:42ZengMDPI AGCells2073-44092025-01-0114210810.3390/cells14020108Blockade of TIPE2-Mediated Ferroptosis of Myeloid-Derived Suppressor Cells Achieves the Full Potential of Combinatory Ferroptosis and Anti-PD-L1 Cancer ImmunotherapyHafiza Kashaf Tariq0Zihao Liang1Lawan Rabiu2Abdulrahman Ibrahim3Nada Mohamady Farouk Abdalsalam4Rong Li5Qiong Yang6Xiaochun Wan7Dehong Yan8Guangdong Immune Cell Therapy Engineering and Technology Research Center, Center for Protein and Cell-Based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, ChinaGuangdong Immune Cell Therapy Engineering and Technology Research Center, Center for Protein and Cell-Based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, ChinaGuangdong Immune Cell Therapy Engineering and Technology Research Center, Center for Protein and Cell-Based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, ChinaGuangdong Immune Cell Therapy Engineering and Technology Research Center, Center for Protein and Cell-Based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, ChinaGuangdong Immune Cell Therapy Engineering and Technology Research Center, Center for Protein and Cell-Based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, ChinaGuangdong Immune Cell Therapy Engineering and Technology Research Center, Center for Protein and Cell-Based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, ChinaSchool of Medicine, South China University of Technology, Guangzhou 510006, ChinaGuangdong Immune Cell Therapy Engineering and Technology Research Center, Center for Protein and Cell-Based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, ChinaGuangdong Immune Cell Therapy Engineering and Technology Research Center, Center for Protein and Cell-Based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, ChinaAlthough immune checkpoint blockade (ICB) therapy has attained unprecedented clinical success, the tolerance and immune suppression mechanisms evolved by tumor cells and their tumor microenvironment (TME) hinder its maximum anti-cancer potential. Ferroptosis therapy can partially improve the efficacy of ICB, but it is still subject to immune suppression by myeloid-derived suppressor cells (MDSCs) in the TME. Recent research suggests that an MDSC blockade can unleash the full therapeutic potential of the combined therapy of ferroptosis and ICB in liver cancer treatment. However, whether blocking the intrinsic ferroptosis pathways of MDSCs can relieve imidazole ketone erastin (IKE)-initiated ferroptosis-induced immune suppression and ultimately trigger the optimal therapeutic effect of the combined ferroptosis and ICB therapy is still unknown. Here, we report that TIPE2, a phospholipid transfer protein, regulated the ferroptosis susceptibility in MDSCs through reprogramming lipid peroxidation-related phosphatidylethanolamine (PE) and phosphatidylcholine (PC) species composition. TIPE2-deficient MDSCs resisted IKE-induced ferroptosis by up-regulating SLC7A11 and GPX4, and dissolved ferroptosis-induced immunosuppressive function by down-regulating lipid ROS whilst encouraging T cell proliferation and infiltration into tumor tissues to improve ferroptosis therapy. More importantly, TIPE2-deficient MDSCs achieved the full anti-tumor therapeutic potential of IKE-induced ferroptosis therapy and a PD-L1 blockade. These findings indicate that TIPE2 confers the ferroptosis sensitivity of MDSCs, and combining the targeting of the TIPE2 of MDSCs, ferroptosis therapy, and ICB is a novel therapeutic option for cancer treatment.https://www.mdpi.com/2073-4409/14/2/108TIPE2MDSCsferroptosisimmune checkpoint blockadecancer treatment |
| spellingShingle | Hafiza Kashaf Tariq Zihao Liang Lawan Rabiu Abdulrahman Ibrahim Nada Mohamady Farouk Abdalsalam Rong Li Qiong Yang Xiaochun Wan Dehong Yan Blockade of TIPE2-Mediated Ferroptosis of Myeloid-Derived Suppressor Cells Achieves the Full Potential of Combinatory Ferroptosis and Anti-PD-L1 Cancer Immunotherapy Cells TIPE2 MDSCs ferroptosis immune checkpoint blockade cancer treatment |
| title | Blockade of TIPE2-Mediated Ferroptosis of Myeloid-Derived Suppressor Cells Achieves the Full Potential of Combinatory Ferroptosis and Anti-PD-L1 Cancer Immunotherapy |
| title_full | Blockade of TIPE2-Mediated Ferroptosis of Myeloid-Derived Suppressor Cells Achieves the Full Potential of Combinatory Ferroptosis and Anti-PD-L1 Cancer Immunotherapy |
| title_fullStr | Blockade of TIPE2-Mediated Ferroptosis of Myeloid-Derived Suppressor Cells Achieves the Full Potential of Combinatory Ferroptosis and Anti-PD-L1 Cancer Immunotherapy |
| title_full_unstemmed | Blockade of TIPE2-Mediated Ferroptosis of Myeloid-Derived Suppressor Cells Achieves the Full Potential of Combinatory Ferroptosis and Anti-PD-L1 Cancer Immunotherapy |
| title_short | Blockade of TIPE2-Mediated Ferroptosis of Myeloid-Derived Suppressor Cells Achieves the Full Potential of Combinatory Ferroptosis and Anti-PD-L1 Cancer Immunotherapy |
| title_sort | blockade of tipe2 mediated ferroptosis of myeloid derived suppressor cells achieves the full potential of combinatory ferroptosis and anti pd l1 cancer immunotherapy |
| topic | TIPE2 MDSCs ferroptosis immune checkpoint blockade cancer treatment |
| url | https://www.mdpi.com/2073-4409/14/2/108 |
| work_keys_str_mv | AT hafizakashaftariq blockadeoftipe2mediatedferroptosisofmyeloidderivedsuppressorcellsachievesthefullpotentialofcombinatoryferroptosisandantipdl1cancerimmunotherapy AT zihaoliang blockadeoftipe2mediatedferroptosisofmyeloidderivedsuppressorcellsachievesthefullpotentialofcombinatoryferroptosisandantipdl1cancerimmunotherapy AT lawanrabiu blockadeoftipe2mediatedferroptosisofmyeloidderivedsuppressorcellsachievesthefullpotentialofcombinatoryferroptosisandantipdl1cancerimmunotherapy AT abdulrahmanibrahim blockadeoftipe2mediatedferroptosisofmyeloidderivedsuppressorcellsachievesthefullpotentialofcombinatoryferroptosisandantipdl1cancerimmunotherapy AT nadamohamadyfaroukabdalsalam blockadeoftipe2mediatedferroptosisofmyeloidderivedsuppressorcellsachievesthefullpotentialofcombinatoryferroptosisandantipdl1cancerimmunotherapy AT rongli blockadeoftipe2mediatedferroptosisofmyeloidderivedsuppressorcellsachievesthefullpotentialofcombinatoryferroptosisandantipdl1cancerimmunotherapy AT qiongyang blockadeoftipe2mediatedferroptosisofmyeloidderivedsuppressorcellsachievesthefullpotentialofcombinatoryferroptosisandantipdl1cancerimmunotherapy AT xiaochunwan blockadeoftipe2mediatedferroptosisofmyeloidderivedsuppressorcellsachievesthefullpotentialofcombinatoryferroptosisandantipdl1cancerimmunotherapy AT dehongyan blockadeoftipe2mediatedferroptosisofmyeloidderivedsuppressorcellsachievesthefullpotentialofcombinatoryferroptosisandantipdl1cancerimmunotherapy |